• About us
• Contact

Advertisement

Organisation › Details

Active Biotech AB (Nasdaq OMX Nordic: ACTI)

Active Biotech AB (OMX NORDIC: ACTI) is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, the primary indication being renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex® for RA. In addition, the preclinical development of the I-3D project is being conducted in cooperation with Chelsea Therapeutics International Ltd. *

 

	Start	1997-01-01 existent
	Group	Active Biotech (Group)
	Predecessor	Active i Malmö AB
	Industry	pharmaceutical
	Industry 2	laquinimod
	Person	Tuvesson, Helén (Active Biotech 201707– CEO before CSO since 201103 before Head Dept Preclinical Developm since 1998)
	Person 2	Kolam, Hans (Active Biotech 201208 CFO)
	Region	Lund
	Country	Sweden
	Street	22 Scheelevägen
	City	223 63 Lund
	Tel	+46-46-192000
		Address record changed: 2020-12-02
Basic data	Employees	C: 51 to 100 (2016-02-24)
	Currency	SEK
	Annual sales	16,275,000 (sales, net, consolidated (2015) 2015-12-31)
	Profit	-193,531,000 (2015-12-31)
	Cash	103,617,000 (2015-12-31)
		* Document for »About Section«:
		Record changed: 2024-02-12

Advertisement

More documents for Active Biotech (Group)

• [1] Active Biotech AB. (8/4/22). "Press Release: Active Biotech Announces a Rights Issue of approximately SEK 55 Million [Not for release in US, AU, CA, JP, et al.]"....
• [2] Active Biotech AB. (12/1/17). "Press Release: Active Biotech Announce Results in ARPEGGIO Phase II Trial with Laquinimod in Primary Progressive MS". Lund....
• [3] Active Biotech AB. (6/19/17). "Press Release: Helén Tuvesson New CEO of Active Biotech AB from July 1, 2017". Lund....
• [4] Active Biotech AB. (5/5/17). "Press Release: Teva and Active Biotech Announce CONCERTO Trial of Laquinimod in RRMS Did Not Meet Primary Endpoint". Jerusalem & Lund....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.